PDCD1 and non-small cell lung carcinoma: In view of the drug approval of checkpoint inhibitors that were first approved by the National Medical Products Administration (NMPA) in China since June 2018, we only included 85 patients with stage IV NSCLC treated with PD-1 inhibitors in detail.